Central Nervous System

 

General pharmacology and behavioural pharmacology 

Anxiolytic potential of sulpiride, clozapine and derivatives in the open-field test,
Pharmacology Biochemistry and Behavior, 36(1), 157-161, (1990).

Comparative study of the behavioural, neurophysiological and motor effects of psychotropic drugs in the dog,
Biological Psychiatry, 27, 1264-1278, (1990).

Can piracetam protect a stabilized operant performance against the amnestic effects of chronic hypoxia treatment ?,
Bulletin of the Japanese Neurochemical Society, 29(1), 450-451, (1990).

Anxiolytic potential of a microgram dose of chlordiazepoxide in the open-field test,
European Journal of Pharmacology, 187, 547-549, (1990).

Effects of low doses of neuroleptics on temporal regulation in a differential reinforcement of response duration (DRRD) schedule in the dog,
Pharmacology, Biochemistry and Behavior, 37(4), 607-611, (1990).

Effect of chronic hypoxic treatment on retention of fixed-interval responding,
Physiology and Behavior, 49(3), 465-470, (1991).

Effects of specific dopaminergic agonists and antagonists in the open-field test,
Pharmacology, Biochemistry and Behavior, 39(2), 367-371, (1991).

Stimulant effect of the beta-carboline FG 7142 in the open-field test,
European Journal of Pharmacology, 200, 183-185, (1991).

Enhanced resistance effect of piracetam upon hypoxia-induced impaired retention of fixed-interval performance in rats,
Pharmacology Biochemistry and Behavior, 40(1), 1-6, (1991).

Comparative study of typical neuroleptics, clozapine and newly synthesised clozapine analogues: correlation between neurochemistry and behaviour,
Behavioural Pharmacology, 3(6), 567-579, (1992).

Differentiation of haloperidol and clozapine using a complex operant schedule in the dog,
Pharmacology Biochemistry and Behavior, 44(1), 181-189, (1993).

Effects of a long-interval retention on the hypoxia-induced impairment of performance in a fixed-interval schedule,
Behavioural Brain Research, 54, 199-203, (1993).

Amineptine improves the performance of dogs in a complex operant temporal regulation schedule,
Pharmacology Biochemistry and Behavior, 45(4), 897-903, (1993).

New pyridobenzodiazepine derivatives as potential antipsychotics: synthesis and neurochemical study,
Journal of Medicinal Chemistry, 36, 2107-2114, (1993).

Pyridobenzoxazepine and pyridobenzothiazepine derivatives as potential central nervous system agents: synthesis and neurochemical study,
Journal of Medicinal Chemistry, 37, 519-525, (1994).

Modulation of the clozapine structure increases its selectivity for the dopamine D4 receptor,
European Journal of Pharmacology, 273, R1-R3, (1995).

New dibenzazepine derivatives with disinhibitory/anxiolytic and antidepressant potentials: behavioural study in the open-field and Porsolt's tests,
Behavioural Pharmacology, 6, 830-838, (1995).

Dibenzoazepine analogues: the electrophysiological properties of JL 3, a potential atypical antidepressant,
European Journal of Pharmacology, 310, 9-12, (1996).

 Facilitatory effects of chronically administered citicoline on learning and memory processes in the dog,
Progress in Neuro-Psychopharmacology and Biological Psychiatry, 22, 115-128, (1998).

Comparative study of pirlindole, a selective RIMA, and its two enantiomers using biochemical and behavioural techniques,
Behavioural Pharmacology, 9, 731-737, (1998).

The oxidation sensitivity could be a useful tool for the detection of the hematotoxicity potential of newly developed molecules: application to antipsychotic drugs,
Archives of Biochemistry and Biophysics, 370(1), 126-137, (1999).

Effect of JL 3, a putative antidepressant, on noradrenergic and serotonergic systems,
European Journal of Pharmacology, 386, 211-216, (1999).

Electrooxidation potential as a tool in the early screening for new safer clozapine-like analogues,
Journal of Medicinal Chemistry, 44(5), 769-776, (2001).

The behavioral effects of acute and chronic JL 13, a putative antipsychotic, in Cebus non-human primates,
Psychopharmacology, 157, 228-235 (2001).

Effects of JL 13, a pyridobenzoxazepine with potential atypical antipsychotic activity, in animal models with schizophrenia,
Journal of Pharmacology and Experimental Therapeutics, 298(1), 1-6 (2001).

Minimal effects of JL 13, a pyridobenzoxazepine derivative with an antipsychotic potential, on circulating prolactin levels in male rats,
Neuroscience Letters, 319, 49-52 (2002).

New pyridobenzodiazepine derivatives: modifications of the basic side chain differentially modulate binding to dopamine (D4.2,D2L) and serotonin (5-HT2A) receptors,
Journal of Medicinal Chemistry, 45, 5136-5149 (2002).

 

Preclinical review 

Clozapine: an atypical neuroleptic,
Neuroscience and Biobehavioural Reviews, 14(4), 357-363, (1990).

Biochemistry of hypoxic damage in brain cells - roles of energy, metabolism, glutamate and calcium ion,
Neurosciences, 17, 375-390, (1991).

Nitric oxide: A new messenger in the brain,
Neuroscience and Biobehavioral Reviews, 17(4), 373-384, (1993).

Diarylazepine derivatives as potent atypical neuroleptic drugs: recent advances,
Current Medicinal Chemistry, 1, 471-501, (1995).

JL13, a pyridobenzoxazepine compound with potential atypical antipsychotic activity: a review of its behavioral properties,
Pharmacological Research, 36 (4), 255-264, (1997).

Pirlindole: a selective reversible inhibitor of monoamine oxidase A. A review of its preclinical properties,
Pharmacological Research, 36, 23-33, (1997).

Dopamine D4 receptors: a new opportunity for research on schizophrenia,
Current Medicinal Chemistry, 5, 77-100, (1998).

 

 

Clinical reviews 

Pirlindole, a reversible and specific monoamine oxidase A inhibitor: A retrospective evaluation of its clinical antidepressant profile,
European Journal of Clinical Research, 9, 225-245, (1997).

Use of normal human intravenous immunoglobulin (IVIg) in the treatment of multifocal motor neuropathy (MMN),
CTD Modules 2.5, 2.7, and 5.

 

 

Clinical trials 

A double-blind randomized placebo-controlled study of the efficacy and safety of pirlindole, a reversible monoamine oxidase A inhibitor in the treatment of depression,
Acta Psychiatrica Scandinavica, 94, 404-410, (1996)

Double-blind randomized controlled study of the efficacy and tolerability of pirlindole, a reversible inhibitor of monoamine oxidase A, and mianserin, in the treatment of depression,
Human Psychopharmacology, 12, 41-46, (1997).

Multicentric open-label study of the efficacy and tolerability of citicoline in the treatment of acute cerebral infarction,
Current Therapeutic Research, 58(5), 309-316, (1997).

Double-blind randomized controlled study of the efficacy and tolerability of two reversible monoamine oxidase A inhibitors, pirlindole and moclobemide, in the treatment of depression,
Acta Psychiatrica Scandinavica, 96(2), 134-141, (1997).